Featured Content
Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent
Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.
Triclosan and Cancer Risk: Is There a Link?
Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.
Is Genomic Medicine Failing Minority Patients?
Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision ...
ARID1A Mutations Might Predict Tumor Response to Immunotherapy
New findings bolster the case for the predictive utility of ARID1A mutations.
Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis
A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free ...More Features>>>
Video Series
-
The Phase 3 PlanB Trial
-
Continue to Work?
-
Drug Resistance to CDK4/6 Inhibitors
-
Comparing Ribociclib and Palbociclib
-
Ribociclib, Abemaciclib, and Palbociclib
-
The Potential of CDK4/6 Inhibitors
-
How Cyclin D Plays A Role
-
Role of Cell Cycle in Progression
-
2016 SABCS: Clinical Insights
-
2016 SABCS: Clinical Insights
-
HER2-positive Metastatic and TNBC
-
Frontline Treatments
-
Treatment-related Neuropathy
-
ER-positive, HER2-negative
-
Emerging Medicines
-
Triple-negative Breast Cancer
-
Insights from the Lab and Clinic
-
Trastuzumab Resistance
-
Biologic Role of HER2
-
Strategies in Management
-
Lapatinib-based Regimen
-
Overcoming Trastuzumab Resistance
-
New Anti-HER2 Agents
-
HER2-targeted Therapies
-
Lapatinib and the Neoadjuvant Tx
-
Predicting Response/Resistance
-
AC-THP vs. TCHP Treatment
Breast Cancer News
Religion, Spirituality, May Influence Physical Health Outcomes in Survivors of Breast Cancer
Ribociclib FDA-Approved For Additional Indications in HR+, HER2- Advanced Breast Cancer
Breast Cancer Resources
More Breast Cancer Information
Polypharmacy and Cancer
The effect of polypharmacy and noncancer mortality on patient survival and other outcomes in cancer varies by study.
Financial Toxicity and Cancer
Though it is clear that cancer is associated with an extreme financial burden, the extent of the burden varies widely.
Dietary Nitrates/Nitrites and Cancer
There is concern that added nitrates and nitrites are associated with an increased risk of cancer, but epidemiologic data have been inconclusive thus far.
Exercise and Cancer
The mechanisms that drive this benefit are not well-understood, and it is believed that the benefit is not just a result of reducing risk factors such as body weight.
Massage and Cancer
An overview of the research regarding the use of massage to improve cancer- or treatment-related symptoms and overall quality of life for patients with cancer.
The Treatment Landscape of Breast Cancer
The treatment landscape in breast cancer has evolved dramatically within the past several decades.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Prostate Cancer | Regimens | Drugs |
| Rare Cancers | Regimens | |
| Renal Cell Carcinoma | Regimens | Drugs |
| Skin Cancer | Regimens | Drugs |
| Urologic Cancers | Regimens | Drugs |
Cancer Therapy Advisor Articles
- BRCA Status Could Inform Pancreatic Cancer Management
- Polypharmacy and Cancer
- Adoptive Cell Therapy in Solid Tumors Demonstrates Robust Antitumor Effects
- Novel Approaches for the Treatment of Primary Central Nervous System Lymphoma
- Heterogeneity of Drug Resistance in EGFR-Mutant Non-Small Cell Lung Cancer